ISIS 104838-CS7, a double-blind, placebo-controlled, randomized trial of the safety, efficacy and pharmacokinetic profile of ISIS 104838 (TNF [tumour necrosis factor]-alpha antisense oligonucleotide) subcutaneous injections in active rheumatoid arthritis patients
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs ISIS 104838 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 22 Oct 2007 Status changed from in progress to completed.
- 28 Oct 2005 New trial record.